Marvel Discovery Corp.
VANCOUVER, BC / ACCESSWIRE / August 10, 2021 / Marvel Discovery Corp. (TSX-V:MARV)(Frankfurt:O4T1)(OTCQB:MARVF); ("Marvel" or the "Company") reports that Karim Rayani (The "Acquiror") both directly, and indirectly through R7 Capital Ventures Ltd. ("R7 Capital"), an investment company wholly owned by Karim Rayani acquired an aggregate of 8,259,000 common shares of Marvel Discovery Corp. ("Marvel") by way of a series of open market purchases on the TSX Venture Exchange. As a result of the July 16th 2021 acquisition of 420,000 common shares in Marvel, the Acquiror now holds 10.5% of the issued and outstanding common shares in the Company.
The Acquiror has paid an aggregate of $794,515.80 representing an average purchase price of approximately $0.0962 per share. On June 28, 2021, R7 Capital, by way of a private placement acquired a further 2,000,000 common units at price of $0.10 cents for an aggregate of $200,000 comprising of one common share and one share purchase warrant exercisable at $0.15 cents for a three-year period. The Acquiror has received incentive stock options to purchase an additional 1,825,000 shares of the Company. Together the shares purchased directly and indirectly, warrants, and stock options received by the Acquiror represents 14.9% of the issued and outstanding common shares of the Company (assuming exercise of all warrants and stock options held).
Mr. Rayani now owns or has control or direction over (8,259,000 common shares representing 10.5%) for a total investment of $794,515.80. Assuming exercise of all stock options and warrants that total would represent 12,369,000 shares (14.9% of Marvel's issued and outstanding common shares).
The shares were acquired by Mr. Rayani for investment purposes. Mr. Rayani may acquire additional securities of Marvel either on the open market, or through private acquisitions, or sell securities of Marvel either on the open market, or through private dispositions, in the future depending on market conditions, reformulation of plans and or relevant factors. Other than the foregoing, Mr. Rayani does not have any plans or any future intentions that relate to, or would result in, any of other foregoing matters.
This press release is issued pursuant to National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also requires a report to be filed with regulatory authorities in each of the jurisdictions in which the Company is a reporting issuer containing information with respect to the foregoing matters (the "Early Warning Report"). A copy of the Early Warning Report will appear with the Company's filings on the System for Electronic Document Analysis and Retrieval (SEDAR)
About Marvel Discovery Corp.
Marvel, listed on the TSX Venture Exchange for over 25 years, is a Canadian based emerging resource company. The Company is systematically exploring its extensive property positions in:
- Newfoundland (Slip, Gander South, Victoria Lake and Hope Brook - Au Prospects)
- Atikokan, Ontario (BlackFly - Au prospect)
- Red Lake, Ontario (Camping Lake - Au prospect)
- Elliot Lake, Ontario (Serpent River/Pecors -Ni-Cu-PGE discovery) & (Uranium- REE's)
- Elliot Lake, Ontario (East Bull - Ni-Cu-PGE prospect)
- Quebec (Duhamel -Ni-Cu-Co prospect & Titanium, Vanadium, and Chromium prospect)
- Prince George, British Columbia (Wicheeda North - Rare Earth Elements prospect)
The Company's website is: https://marveldiscovery.ca/
ON BEHALF OF THE BOARD
Marvel Discovery Corp.
"Karim Rayani"
Karim Rayani
President/Chief Executive Officer, Director
Tel: 604 716 0551 Email: k@r7.capital
Disclaimer for Forward-Looking Information:
Certain statements in this release are forward-looking statements which reflect the expectations of management. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Forward-looking statements in this press release relate to, among other things: completion of the proposed Arrangement. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions, and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Except as required by law, the Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Marvel Discovery Corp.
View source version on accesswire.com:
https://www.accesswire.com/659217/Early-Warning-Press-Release-Regarding-Investment-in-Marvel-Discovery-Corp
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India27.10.2025 13:45:00 CET | Press release
Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad's Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continui
Sauce Labs and Deque Systems Partner to Deliver Comprehensive Accessibility Testing at Scale24.10.2025 07:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 24, 2025 / Sauce Labs Inc., a leading provider of continuous testing solutions, and Deque Systems, Inc., a trusted leader in digital accessibility, today announced a strategic partnership to help companies ensure compliance with accessibility regulations and deliver accessible digital experiences across all devices and platforms. The collaboration combines Sauce Labs' extensive real-device coverage and scalable cloud infrastructure with Deque's unparalleled accessibility expertise. This partnership is a renewed commitment, building on a long-standing relationship between the two companies. By doubling down on their joint offering, Sauce Labs and Deque are providing a comprehensive solution for accessibility testing at scale. The partnership addresses the growing need for businesses to meet digital accessibility standards, especially with the upcoming European Accessibility Act (EAA), which became law on June 28, 2025. The EAA requires produ
Florence Connects 65,000+ Study Sites and 600+ Sponsors Worldwide - Unleashing the Next Era of Clinical Trial Intelligence23.10.2025 14:00:00 CEST | Press release
With the industry's largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational risk management. ATLANTA, GA / ACCESS Newswire / October 23, 2025 / Florence Healthcare reinforced its position as the global leader in clinical trial operations with a major milestone: Florence Trial Operations Platform now connects 65,000 study sites spanning more than 600 sponsors across 90+ countries, forming the industry's largest network. Recognized as the #1 clinical trial technology for six consecutive years, Florence continues to set the standard for startup speed, workflow automation, and operational risk management across sponsor study portfolios. "Florence was built to bring sponsors and sites into a shared operational space," said Ryan Jones, CEO of Florence Healthcare. "First, we fully digitized startup to eliminate manual bottlenecks and paper workflows. Now, we're using AI to enhance speed and augment intelligence across 65,000 s
U.S. Polo Assn. Wins Gold and Silver Stevie Awards at the 2025 International Business Awards in Lisbon, Portugal23.10.2025 13:00:00 CEST | Press release
LISBON, PT AND WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been awarded two prestigious Stevie® Awards from the 22nd Annual International Business Awards® (IBA).U.S. Polo Assn. Wins Two Stevie® Awards U.S. Polo Assn. was celebrated during an elegant gala event at the Corinthia Hotel in Lisbon, Portugal, on Friday, October 10, attended by leadership from USPA Global and the brand's strategic partners in the region. The global event hosted over 350 guests from more than 30 nations, including many of the world's top companies and Stevie winners, including Coca-Cola, Starbucks, Lenovo, Kendra Scott, IBM, and Turkish Airlines. The brand's winning entries included a Gold Stevie Award for 'Achievement in International Expansion' and a Silver Stevie Award in 'Celebration Event' for the 2024 Paris Games Polo Challenge campaign. The multi-billion-dollar, sp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
